



ASX & MEDIA RELEASE

2 DECEMBER 2019

NANABIS™ OBSERVATIONAL STUDY UNDERWAY – WITH IMPRESSIVE START

- 10% recruited ahead of formal national launch
- Over 100 Australian Doctors and 200 patients have been enrolled in the Observational Study
- Patients have reported a reduction in pain in all cases currently
- Ready for formal National rollout in January 2020
- Contributing to strong sales growth under the TGA Special Access Scheme previously reported to the ASX on 11 November

Medlab Clinical Ltd (ASX: MDC) is extremely pleased to announce study progression in its Australian approved Ethics Observational Study (ACTRN # ACTRN12619000513112) for NanaBis™. ***The Study is part of the Medlab's commitment to clinical trials pathway to drug registration for NanaBis that includes the current study close to completion at The Royal North Shore Hospital in Sydney.***

On 18 June 2019, MDC announced Ethics approval for the second NanaBis™ Study, the Observational Study to assess real world use of NanaBis™, provide further evidence for safety and tolerability and review the impact NanaBis™ has on current prescriptive medicines used in pain settings, thus bolstering MDC's ultimate goal of drug registration.

Because of the sensitivity of the patient data, for the last 12 weeks Medlab has soft launched the study to test and harden the process around data collection, transport and management. These tests have all successfully concluded.

Today Medlab has completed its 1st monitoring process as per the Study Protocol and is very pleased with the data to date:

- Over 100 Australian Doctors so far have agreed and are participating in the study
- Over 200 Australian Patients, representing 10% of the anticipated cohort have been invited to participate and have been successfully recruited into the study, of which 66% are female with an average age of 56 years.
- Dosage guidelines averaged to be 2 sprays per day which is well below the dosage models used in the RNSH NanaBis™ (#ACTRN12617001480370) trial, with all patients reporting pain reductions.
- 50% of the recruited patients were diagnosed with neuropathic pain.

Dr Sean Hall, CEO of MDC said, "this Observational Study is critical in understanding real world use, dosing in relation to other prescribed medications and any potential effects to the patient. The Study is a unique vehicle protecting Medlab, the Doctor and patient under an Ethics agreement. Moving forward, we are very optimistic as to the NanaBis™ benefit for the assumed patient cohort."

Further to Dr Hall's statement, Prof Luis Vitetta, Director of Medical Research at Medlab, also stated, "An observational study on the safety, tolerability and efficacy of Medlab's cannabis-based medicine NanaBis™ is providing extremely noteworthy and very encouraging results for the effective management of pain, as well as the future development of the company's cannabis-based medicines."

Medlab is expecting to formally launch the Observational Study, nationally in January.

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: DR SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.